SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

2/6/23 8:59:24 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $AMGN alert in real time by email

SC 13G/A 1 Amgen_Inc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING AMGEN INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 031162100 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER PAGE SHALL BE FILLED OUT FOR A REPORTING PERSON`S INITIAL FILING ON THIS FORM WITH RESPECT TO THE SUBJECT CLASS OF SECURITIES, AND FOR ANY SUBSEQUENT AMENDMENT CONTAINING INFORMATION WHICH WOULD ALTER THE DISCLOSURES PROVIDED IN A PRIOR COVER PAGE. THE INFORMATION REQUIRED IN THE REMAINDER OF THIS COVER PAGE SHALL NOT BE DEEMED TO BE "FILED" FOR THE PURPOSE OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934 ("ACT") OR OTHERWISE SUBJECT TO THE LIABILITIES OF THAT SECTION OF THE ACT BUT SHALL BE SUBJECT TO ALL OTHER PROVISIONS OF THE ACT (HOWEVER, SEE THE NOTES). CUSIP NO: 031162100 13G PAGE 2 OF 5 PAGES 1. NAME OF REPORTING PERSON: STATE STREET CORPORATION I.R.S. IDENTIFICATION NO. OF THE ABOVE PERSON: 04-2456637 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP NOT APPLICABLE 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION BOSTON, MASSACHUSETTS 5. SOLE VOTING POWER 0 SHARES 6. SHARED VOTING POWER 20,769,879 7. SOLE DISPOSITIVE POWER 0 SHARES 8. SHARED DISPOSITIVE POWER 29,679,087 9. AGGREGATED AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 29,760,088 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES NOT APPLICABLE 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.58% 12. TYPE OF REPORTING PERSON HC CUSIP NO: 031162100 13G PAGE 3 OF 5 PAGES ITEM 1. (A) NAME OF ISSUER AMGEN INC (B) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES 1 AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 UNITED STATES ITEM 2. (A) NAME OF PERSON FILING STATE STREET CORPORATION (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE STATE STREET FINANCIAL CENTER ONE LINCOLN STREET BOSTON, MA 02111 (FOR ALL REPORTING PERSONS) (C) CITIZENSHIP: SEE ITEM 4 (CITIZENSHIP OR PLACE OF ORGANIZATION) OF COVER PAGES (D) TITLE OF CLASS OF SECURITIES COMMON STOCK (E) CUSIP NUMBER: 031162100 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A: SEE ITEM 12(TYPE OF REPORTING PERSON) OF THE COVER PAGE FOR EACH REPORTING PERSON AND THE TABLE BELOW, WHICH EXPLAINS THE MEANING OF THE TWO LETTER SYMBOLS APPEARING IN ITEM 12 OF THE COVER PAGES. SYMBOL CATEGORY BK BANK AS DEFINED IN SECTION 3(A) (6) OF THE ACT. IC INSURANCE COMPANY AS DEFINED IN SECTION 3 (A) (19) OF THE ACT IC INVESTMENT COMPANY REGISTERED UNDER SECTION 8 OF THE INVESTMENT COMPANY ACT OF 1940. IA AN INVESTMENT ADVISOR IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (E). EP AN EMPLOYEE BENEFIT PLAN OR ENDOWMENT FUND IN ACCORDANCE WITH RULE 13D-1(B) (1) (II) (F) . HC A PARENT HOLDING COMPANY OR CONTROL PERSON IN ACCORDANCE WITH RULE 13D-1(B)(1)(II) (G). SA A SAVINGS ASSOCIATIONS AS DEFINED IN SECTION 3(B) OF THE FEDERAL DEPOSIT INSURANCE ACT (12 U.S.C. 1813). CP A CHURCH PLAN THAT IS EXCLUDED FROM THE DEFINITION OF AN INVESTMENT COMPANY UNDER SECTION 3(C)(14) OF THE INVESTMENT COMPANY ACT OF 1940. CUSIP NO: 031162100 13G PAGE 4 OF 5 PAGES ITEM 4. OWNERSHIP THE INFORMATION SET FORTH IN ROWS 5 THROUGH 11 OF THE COVER PAGE HERETO FOR EACH OF THE REPORTING PERSONS IS INCORPORATED HEREIN BY REFERENCE. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF CLASS NOT APPLICABLE ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON NOT APPLICABLE ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON SEE EXHIBIT 1 ATTACHED HERETO ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP NOT APPLICABLE ITEM 9. NOTICE OF DISSOLUTION OF GROUP NOT APPLICABLE CUSIP NO: 031162100 13G PAGE 5 OF 5 PAGES ITEM 10. CERTIFICATION BY SIGNING BELOW I CERTIFY THAT, TO THE BEST OF MY KNOWLEDGE AND BELIEF, THE SECURITIES REFERRED TO ABOVE WERE ACQUIRED AND ARE HELD IN THE ORDINARY COURSE OF BUSINESS AND WERE NOT ACQUIRED AND ARE NOT HELD FOR THE PURPOSE OR WITH THE EFFECT OF CHANGING OR INFLUENCING THE CONTROL OF THE ISSUER OF THE SECURITIES AND WERE NOT ACQUIRED AND ARE NOT HELD IN CONNECTION WITH OR AS A PARTICIPANT IN ANY TRANSACTION HAVING THAT PURPOSE OR EFFECT. SIGNATURES AFTER REASONABLE INQUIRY AND TO THE BEST OF HIS KNOWLEDGE AND BELIEF, EACH OF THE UNDERSIGNED CERTIFIES THAT THE INFORMATION SET FORTH IN THIS STATEMENT IS TRUE, COMPLETE AND CORRECT. STATE STREET CORPORATION ELIZABETH SCHAEFER SENIOR VICE PRESIDENT, DEPUTY CONTROLLER EXHIBIT 1 THE FOLLOWING TABLE LISTS THE IDENTITY AND ITEM 3 CLASSIFICATION OF EACH SUBSIDIARY OF STATE STREET CORPORATION, THE PARENT HOLDING COMPANY, THAT BENEFICIALLY OWNS THE ISSUER`S SECURITIES. PLEASE REFER TO ITEM 3 OF THE ATTACHED SCHEDULE 13G FOR A DESCRIPTION OF EACH OF THE TWO-LETTER SYMBOLS REPRESENTING THE ITEM 3 CLASSIFICATION BELOW. SUBSIDIARY ITEM 3 CLASSIFICATION STATE STREET BANK AND TRUST COMPANY BK SSGA FUNDS MANAGEMENT, INC. IA STATE STREET GLOBAL ADVISORS EUROPE LIMITED IA STATE STREET GLOBAL ADVISORS LIMITED IA STATE STREET GLOBAL ADVISORS TRUST COMPANY IA STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED IA STATE STREET GLOBAL ADVISORS (JAPAN) CO., LTD. IA STATE STREET GLOBAL ADVISORS ASIA LIMITED IA STATE STREET GLOBAL ADVISORS, LTD. IA STATE STREET GLOBAL ADVISORS SINGAPORE LIMITED IA STATE STREET SAUDI ARABIA FINANCIAL SOLUTIONS COMPANY IA NOTE: ALL OF THE LEGAL ENTITIES ABOVE ARE DIRECT OR INDIRECT SUBSIDIARIES OF STATE STREET CORPORATION.

Get the next $AMGN alert in real time by email

Recent Analyst Ratings for

$AMGN

Date	Price Target	Rating	Analyst
12/10/2024	$256.00	Underperform	BofA Securities
11/15/2024		Peer Perform	Wolfe Research
11/14/2024	$335.00	Neutral	Citigroup
10/17/2024	$380.00	Outperform	Bernstein
10/14/2024	$320.00 → $333.00	Buy → Hold	Truist
9/27/2024	$405.00	Overweight	Cantor Fitzgerald
8/7/2024	$320.00 → $335.00	Overweight → Equal Weight	Wells Fargo
5/3/2024	$230.00 → $300.00	Underweight → Equal Weight	Barclays

More analyst ratings

SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $AMGN

$AMGN SEC Filings

SEC Form DEFA14A filed by Amgen Inc.

SEC Form DEF 14A filed by Amgen Inc.

SEC Form 144 filed by Amgen Inc.

$AMGN Financials

Live finance-specific insights

IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE

UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS

$AMGN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, Operations Santos Esteban covered exercise/tax liability with 3,393 shares, decreasing direct ownership by 4% to 75,075 units (SEC Form 4)

EVP & Chief Technology Officer Reese David M covered exercise/tax liability with 3,635 shares, decreasing direct ownership by 8% to 40,702 units (SEC Form 4)

SVP, Human Resources Miller Derek covered exercise/tax liability with 930 shares, decreasing direct ownership by 9% to 9,654 units (SEC Form 4)

$AMGN Leadership Updates

Live Leadership Updates

GeminiBio Appoints Mike Stella to Board

Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS

$AMGN Press Releases

Fastest customizable press release news feed in the world

IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE

UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS

$AMGN FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for REPATHA issued to AMGEN INC

FDA Approval for PAVBLU issued to AMGEN INC

FDA Approval for REPATHA issued to AMGEN INC

$AMGN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

BofA Securities resumed coverage on Amgen with a new price target

Wolfe Research initiated coverage on Amgen

Citigroup initiated coverage on Amgen with a new price target

$AMGN Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

SEC Form SC 13D filed by Amgen Inc.

$AMGN Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Amgen Inc converted options into 33,603,948 shares and bought $29,999,985 worth of shares (1,764,705 units at $17.00)

Recent Analyst Ratings for
$AMGN

$AMGN
SEC Filings

$AMGN
Financials

$AMGN
Insider Trading

$AMGN
Leadership Updates

$AMGN
Press Releases

$AMGN
FDA approvals

$AMGN
Analyst Ratings

$AMGN
Large Ownership Changes

$AMGN
Insider Purchases